JP2014512363A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014512363A5 JP2014512363A5 JP2014504058A JP2014504058A JP2014512363A5 JP 2014512363 A5 JP2014512363 A5 JP 2014512363A5 JP 2014504058 A JP2014504058 A JP 2014504058A JP 2014504058 A JP2014504058 A JP 2014504058A JP 2014512363 A5 JP2014512363 A5 JP 2014512363A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- masp
- mbl
- wallis
- letter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161473698P | 2011-04-08 | 2011-04-08 | |
| US61/473,698 | 2011-04-08 | ||
| PCT/US2012/032650 WO2012139081A2 (en) | 2011-04-08 | 2012-04-06 | Methods for treating conditions associated with masp-2 dependent complement activation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016095034A Division JP6239030B2 (ja) | 2011-04-08 | 2016-05-11 | Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014512363A JP2014512363A (ja) | 2014-05-22 |
| JP2014512363A5 true JP2014512363A5 (https=) | 2014-09-11 |
| JP5937197B2 JP5937197B2 (ja) | 2016-06-22 |
Family
ID=46966283
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014504058A Active JP5937197B2 (ja) | 2011-04-08 | 2012-04-06 | Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法 |
| JP2016095034A Active JP6239030B2 (ja) | 2011-04-08 | 2016-05-11 | Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法 |
| JP2017209894A Active JP6584476B2 (ja) | 2011-04-08 | 2017-10-31 | Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法 |
| JP2019160040A Active JP6893539B2 (ja) | 2011-04-08 | 2019-09-03 | Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016095034A Active JP6239030B2 (ja) | 2011-04-08 | 2016-05-11 | Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法 |
| JP2017209894A Active JP6584476B2 (ja) | 2011-04-08 | 2017-10-31 | Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法 |
| JP2019160040A Active JP6893539B2 (ja) | 2011-04-08 | 2019-09-03 | Ｍａｓｐ−２依存性補体活性化に関連した状態を治療するための方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US8951522B2 (https=) |
| EP (3) | EP3964233A1 (https=) |
| JP (4) | JP5937197B2 (https=) |
| KR (6) | KR101870915B1 (https=) |
| CN (3) | CN110075294A (https=) |
| AU (1) | AU2012239889B2 (https=) |
| BR (1) | BR112013025917A2 (https=) |
| CA (4) | CA3076975C (https=) |
| CL (1) | CL2013002874A1 (https=) |
| DK (2) | DK2694108T3 (https=) |
| ES (2) | ES2683307T3 (https=) |
| IL (3) | IL228758B (https=) |
| MX (3) | MX381987B (https=) |
| NZ (5) | NZ731596A (https=) |
| PL (1) | PL3287142T3 (https=) |
| RU (2) | RU2743409C2 (https=) |
| WO (1) | WO2012139081A2 (https=) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0688182B2 (ja) | 1986-09-08 | 1994-11-09 | バブコツク日立株式会社 | スタツド着脱装置 |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| KR101870915B1 (ko) | 2011-04-08 | 2018-06-25 | 유니버시티 오브 레스터 | Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법 |
| US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| PE20150159A1 (es) * | 2011-12-21 | 2015-02-08 | Novartis Ag | Composiciones y metodos para anticuerpos que actuan sobre el factor p |
| WO2013180834A2 (en) * | 2012-04-06 | 2013-12-05 | Omeros Corporation | Compositions and methods of inhibting masp-1 and/or masp-3 for the treatment of paroxysmal nocturnal hemoglobinuria |
| KR102339315B1 (ko) * | 2012-06-18 | 2021-12-15 | 오메로스 코포레이션 | 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법 |
| CN104870475B (zh) | 2012-10-25 | 2019-11-08 | 美国比奥维拉迪维股份有限公司 | 抗补体C1s抗体和其用途 |
| DK2914291T3 (da) | 2012-11-02 | 2022-05-16 | Bioverativ Usa Inc | Anti-komplement-c1s-antistoffer og anvendelser deraf |
| US20140363433A1 (en) | 2013-03-15 | 2014-12-11 | Omeros Corporation | Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same |
| ES2964340T3 (es) | 2013-03-15 | 2024-04-05 | Omeros Corp | Métodos para generar anticuerpos portadores de péptidos bioactivos y composiciones que comprenden los mismos |
| SMT202000659T1 (it) * | 2013-10-17 | 2021-01-05 | Omeros Corp | Metodi per il trattamento delle condizioni associate all'attivazione del complemento dipendente dalla masp-2 |
| WO2015070041A1 (en) * | 2013-11-08 | 2015-05-14 | Icahn School Of Medicine At Mount Sinai | Methods for monitoring kidney dysfunction |
| AU2015274482B2 (en) | 2014-06-12 | 2018-11-08 | Ucb Holdings, Inc. | Modulation of complement activity |
| EP3250230B9 (en) | 2015-01-28 | 2022-02-23 | RA Pharmaceuticals, Inc. | Modulators of complement activity |
| WO2016164358A1 (en) | 2015-04-06 | 2016-10-13 | True North Therapeutics, Inc. | Humanized anti-c1s antibodies and methods of use thereof |
| CN108472347B (zh) | 2015-11-09 | 2023-09-05 | 奥默罗斯公司 | 用于治疗与masp-2依赖性补体活化相关的病况的方法 |
| ES2941640T3 (es) | 2015-12-16 | 2023-05-24 | Ra Pharmaceuticals Inc | Moduladores de la actividad del complemento |
| MX2018007392A (es) * | 2015-12-23 | 2018-08-15 | Greenovation Biotech Gmbh | Polipeptidos para inhibir la activacion del complemento. |
| US10736960B2 (en) * | 2016-01-05 | 2020-08-11 | Omeros Corporation | Methods for inhibiting fibrosis in a subject in need thereof |
| WO2017173290A1 (en) | 2016-03-31 | 2017-10-05 | Omeros Corporation | Methods for inhibiting angiogenesis in a subject in need thereof |
| UY37376A (es) * | 2016-08-26 | 2018-03-23 | Amgen Inc | Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso |
| JOP20170170B1 (ar) * | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
| HUE073475T2 (hu) | 2016-10-12 | 2026-01-28 | Bioverativ Usa Inc | C1s elleni antitestek és alkalmazási eljárásaik |
| IL265981B2 (en) * | 2016-10-13 | 2025-05-01 | Univ Leicester | Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy |
| MX2019006527A (es) | 2016-12-07 | 2019-08-01 | Ra Pharmaceuticals Inc | Moduladores de la actividad del complemento. |
| JP6442703B2 (ja) * | 2016-12-26 | 2018-12-26 | 日本ビーシージー製造株式会社 | 細菌細胞壁骨格成分を含有する水中油型エマルション製剤 |
| JPWO2018164186A1 (ja) * | 2017-03-09 | 2020-01-09 | 協和キリン株式会社 | Ｍａｓｐ２の発現を抑制する核酸 |
| AU2018306411B2 (en) * | 2017-07-28 | 2022-03-31 | Lemonex Inc. | Pharmaceutical composition for preventing or treating liver cancer |
| WO2019105437A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN110945130B (zh) | 2017-12-01 | 2024-04-09 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| JP7365052B2 (ja) | 2017-12-01 | 2023-10-19 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| WO2019105435A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| BR112020010916A2 (pt) | 2017-12-04 | 2020-11-17 | Ra Pharmaceuticals, Inc | moduladores da atividade do complemento |
| GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
| CN112867706B (zh) | 2018-05-29 | 2024-11-15 | 奥默罗斯公司 | Masp-2抑制剂和使用方法 |
| RU2699040C1 (ru) * | 2018-07-23 | 2019-09-03 | Федеральное государственное бюджетное учреждение науки "Уральский научно-практический центр радиационной медицины Федерального медико-биологического агентства" (ФГБУН УНПЦ РМ ФМБА России) | Способ экстренной профилактики и лечения острой лучевой болезни (варианты) |
| US11918600B2 (en) | 2018-08-21 | 2024-03-05 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof |
| EP3628735A1 (en) * | 2018-09-25 | 2020-04-01 | Centre National De La Recherche Scientifique | Antisense rna targeting pmp22 for the treatment of charcot-marie-tooth 1a disease |
| EP3862024A4 (en) | 2018-09-30 | 2022-08-17 | Suzhou Ribo Life Science Co., Ltd. | SIRNA CONJUGATE, METHOD FOR ITS PRODUCTION AND ITS USE |
| BR112021008967A2 (pt) * | 2018-11-15 | 2021-08-17 | Ionis Pharmaceuticals, Inc. | moduladores da expressão de irf5 |
| EP3960858B1 (en) * | 2018-12-25 | 2025-05-07 | Beijing Baishihekang Pharmaceutical Technology (BSJpharma) Co., Ltd. | Small rna medicament for prevention and treatment of inflammation-related diseases and combination thereof |
| US12496347B2 (en) | 2018-12-28 | 2025-12-16 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof |
| EP3934675A2 (en) | 2019-03-08 | 2022-01-12 | RA Pharmaceuticals, Inc. | Zilucoplan as deep tissue penetrating c5 inhibitor |
| JP7530106B2 (ja) * | 2019-03-14 | 2024-08-07 | レナセラピューティクス株式会社 | Ｉｈｈ発現を調節するための核酸複合体 |
| CA3134614A1 (en) | 2019-03-29 | 2020-10-08 | Ra Pharmaceuticals, Inc. | Complement modulators and related methods |
| BR112021017820A2 (pt) | 2019-04-24 | 2022-02-08 | Ra Pharmaceuticals Inc | Composições e métodos para modulação da atividade de complemento |
| WO2020233680A1 (zh) | 2019-05-22 | 2020-11-26 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| WO2020233651A1 (zh) * | 2019-05-22 | 2020-11-26 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| AU2020280438B2 (en) | 2019-05-22 | 2025-03-06 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| JP7610268B2 (ja) | 2019-05-22 | 2025-01-08 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
| EP3978609A4 (en) | 2019-05-24 | 2024-02-07 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| CN113966224A (zh) | 2019-06-04 | 2022-01-21 | Ra制药公司 | 采用补体抑制剂的炎性疾病治疗 |
| CN111024947A (zh) * | 2019-11-19 | 2020-04-17 | 江苏美克医学技术有限公司 | 白色念珠菌荧光免疫层析测定试剂盒及其制备方法 |
| WO2021107057A1 (ja) | 2019-11-27 | 2021-06-03 | 京セラ株式会社 | 通信制御方法及びユーザ装置 |
| BR112022010881A2 (pt) | 2019-12-04 | 2022-08-23 | Omeros Corp | Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado a serina protease-2 associada à lectina de ligação ao manan |
| IL293550A (en) | 2019-12-04 | 2022-08-01 | Omeros Corp | 2-masp inhibitor compounds, preparations containing them and their uses |
| JP7699389B2 (ja) | 2019-12-04 | 2025-06-27 | オメロス コーポレーション | Ｍａｓｐ－２阻害剤および使用方法 |
| EP4069676A1 (en) | 2019-12-04 | 2022-10-12 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| WO2021168148A1 (en) * | 2020-02-19 | 2021-08-26 | Alnylam Pharmaceuticals, Inc. | Mannan binding lectin serine peptidase 2 (masp2) irna compositions and methods of use thereof |
| KR102314642B1 (ko) * | 2020-04-17 | 2021-10-20 | 재단법인 아산사회복지재단 | 파브리 병 진단용 바이오 마커 및 이의 용도 |
| WO2021231720A1 (en) * | 2020-05-15 | 2021-11-18 | Alexion Pharmaceuticals, Inc. | Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease |
| CN113674860B (zh) * | 2020-05-15 | 2024-05-17 | 北京大学人民医院 | 一种难治性iTTP风险预测装置、系统及其应用 |
| AU2021293174A1 (en) | 2020-06-14 | 2023-01-19 | Vertex Pharmaceuticals Incorporated | Complement Factor I-related compositions and methods |
| US12383547B2 (en) | 2020-07-01 | 2025-08-12 | Vanderbilt University | Methods of treatment for a kidney disease |
| CN114634575B (zh) * | 2020-12-16 | 2025-04-11 | 康诺亚生物医药科技（成都）有限公司 | 一种补体抑制剂的开发和应用 |
| TW202305010A (zh) * | 2021-04-25 | 2023-02-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗ｍａｓｐ２抗體、其抗原結合片段及醫藥用途 |
| WO2023108028A2 (en) | 2021-12-10 | 2023-06-15 | Omeros Corporation | Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof |
| IL317825A (en) * | 2022-07-25 | 2025-02-01 | Amgen Inc | RNA interference constructs and methods for inhibiting fam13a expression |
| JP2025541737A (ja) | 2022-11-30 | 2025-12-23 | オメロス コーポレーション | Ｍａｓｐ－２阻害物質としての縮合ピリミジン |
| US20250122225A1 (en) | 2023-10-06 | 2025-04-17 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| CN119978131B (zh) * | 2025-04-15 | 2025-06-27 | 北京赛斯维德生物科技有限公司 | 一种血管性血友病因子裂解蛋白酶(adamts13)单克隆抗体、制备方法及应用 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4394370A (en) | 1981-09-21 | 1983-07-19 | Jefferies Steven R | Bone graft material for osseous defects and method of making same |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4526909A (en) | 1984-01-09 | 1985-07-02 | Regents Of The University Of California | Polymethylmethacrylate delivery system for bone morphogenetic protein |
| US4563489A (en) | 1984-02-10 | 1986-01-07 | University Of California | Biodegradable organic polymer delivery system for bone morphogenetic protein |
| JPH0662679B2 (ja) | 1985-06-21 | 1994-08-17 | 新田ゼラチン株式会社 | 組織親和性コラ−ゲンとその製法 |
| US5453566A (en) | 1986-03-28 | 1995-09-26 | Calgene, Inc. | Antisense regulation of gene expression in plant/cells |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| ATE115999T1 (de) | 1987-12-15 | 1995-01-15 | Gene Shears Pty Ltd | Ribozyme. |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8822492D0 (en) | 1988-09-24 | 1988-10-26 | Considine J | Apparatus for removing tumours from hollow organs of body |
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| US6075181A (en) * | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| SG46445A1 (en) | 1990-01-26 | 1998-02-20 | Immunomedics Inc | Vaccines against cancer and infectious diseases |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| US5789573A (en) | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| IL108367A0 (en) | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5856121A (en) | 1994-02-24 | 1999-01-05 | Case Western Reserve University | Growth arrest homebox gene |
| JPH07238100A (ja) | 1994-02-25 | 1995-09-12 | Sumitomo Electric Ind Ltd | ヒトのｍａｓｐに対するモノクローナル抗体 |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| AU4467396A (en) | 1994-12-12 | 1996-07-10 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain, inflammation and spasm |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| US5739119A (en) | 1996-11-15 | 1998-04-14 | Galli; Rachel L. | Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA |
| US7083786B2 (en) | 1997-04-03 | 2006-08-01 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
| US6297024B1 (en) | 1998-10-15 | 2001-10-02 | Cell Activation, Inc. | Methods for assessing complement activation |
| JP2002532079A (ja) | 1998-12-15 | 2002-10-02 | ザ ブライハム アンド ウイミンズ ホスピタル， インコーポレイテッド | 補体活性化に関連するレクチン補体経路を調節するための方法および産物 |
| US7273925B1 (en) | 1998-12-15 | 2007-09-25 | Brigham And Women's Hospital, Inc. | Methods and products for regulating lectin complement pathway associated complement activation |
| US6235494B1 (en) | 1999-02-08 | 2001-05-22 | The Scripps Research Institute | Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates |
| RU2271825C2 (ru) | 1999-07-21 | 2006-03-20 | Омерос Корпорейшн | Растворы и способы ингибирования боли, воспаления и разрушения хряща |
| US6794132B2 (en) | 1999-10-02 | 2004-09-21 | Biosite, Inc. | Human antibodies |
| US20030186419A1 (en) | 1999-12-02 | 2003-10-02 | Jensenius Jens Christian | Masp-3, a complement-fixing enzyme, and uses for it |
| US6649592B1 (en) | 2000-01-14 | 2003-11-18 | Science & Technology Corporation @ Unm | Peptide inhibitors of LFA-1/ICAM-1 interaction |
| SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
| NZ523900A (en) | 2000-07-13 | 2004-02-27 | Jens Christian Jensenius | Isolation and characterisation of a mannan-binding lectin (MBL) associated serine protease (MASP-2) and uses thereof to treat infections |
| CA2454562A1 (en) | 2001-07-26 | 2003-02-06 | Alexion Pharmaceuticals, Inc. | Method of improving cognitive function |
| EP1496835A4 (en) | 2002-02-01 | 2006-10-18 | Omeros Corp | COMPOSITIONS AND METHODS FOR THE SYSTEMIC SUPPRESSION OF CARTON DECOMPOSITION |
| WO2003081206A2 (en) | 2002-03-18 | 2003-10-02 | Alexion Pharmaceuticals, Inc. | Stratification of patient populations having or suspected of having rheumatoid arthritis |
| AU2003249317B2 (en) | 2002-07-19 | 2007-08-02 | Institute Of Materials Research And Engineering | Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from |
| PT1534313E (pt) | 2002-07-30 | 2013-01-25 | Omeros Corp | Soluções e método de irrigação oftalmológica |
| ITRM20020511A1 (it) * | 2002-10-09 | 2004-04-10 | Santa Anna Acuto | Uso dell'insulator sns di riccio di mare per la terapia genica di malattie delle cellule eritroidi. |
| EP1570075A2 (en) | 2002-12-03 | 2005-09-07 | Aarhus Universitet | Method for determing predisposition to manifestation of immune system related diseases |
| AU2004216176B2 (en) | 2003-02-21 | 2008-04-03 | Genentech, Inc. | Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury |
| EP1609804B1 (en) * | 2003-03-17 | 2012-06-13 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Construct comprising recognition domain of antibody against von willebrand factor-specific cleaving enzyme |
| EP1625166B1 (en) | 2003-05-12 | 2015-04-08 | Helion Biotech ApS | Antibodies to masp-2 |
| US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| EP2386316B1 (en) * | 2004-06-10 | 2018-02-28 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| WO2005123776A1 (en) | 2004-06-10 | 2005-12-29 | Omeros Corporation | Methods for treating conditions associated with lectin-dependent complement activation |
| US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| GB0412966D0 (en) | 2004-06-10 | 2004-07-14 | Univ Leicester | Genetically modified non-human mammals and cells |
| US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| WO2006133955A1 (en) | 2005-06-17 | 2006-12-21 | Baxter International Inc. | Adamts13-comprising compositions having thrombolytic activity |
| EP1987354B1 (en) | 2006-01-27 | 2010-11-03 | Rappaport Family Institute for Research in the Medical Sciences | Methods for determining blood coagulation |
| KR101584468B1 (ko) | 2006-03-08 | 2016-01-13 | 아케믹스 엘엘씨 | 안질환의 치료에 유용한 보체 결합 앱타머 및 항-ｃ5 제제 |
| LT2894165T (lt) | 2008-11-10 | 2023-03-10 | Alexion Pharmaceuticals, Inc. | Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui |
| NZ597259A (en) | 2009-06-23 | 2014-04-30 | Alexion Pharma Inc | Bispecific antibodies that bind to complement proteins |
| US20120282285A1 (en) | 2009-07-17 | 2012-11-08 | Rigshospitalet | Masp isoforms as inhibitors of complement activation |
| CN102781471B (zh) | 2009-10-16 | 2016-10-12 | 奥默罗斯公司 | 通过抑制masp-2依赖性补体活化治疗弥散性血管内凝血的方法 |
| MX2012005151A (es) * | 2009-11-05 | 2012-08-23 | Federico Ii University Of Naples | Tratamiento de hemoglobinuria nocturna paroxismica, anemias hemoliticas y estados de enfermedad que involucran hemolisis intravascular y extravascular. |
| WO2011109338A1 (en) | 2010-03-01 | 2011-09-09 | Alexion Pharmaceuticals Inc. | Methods and compositions for treating degos' disease |
| US20150166676A1 (en) | 2011-04-08 | 2015-06-18 | Omeros Corporation | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
| US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| KR101870915B1 (ko) | 2011-04-08 | 2018-06-25 | 유니버시티 오브 레스터 | Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법 |
| EP2704743B1 (en) | 2011-05-04 | 2020-03-11 | Omeros Corporation | Compositions for inhibiting masp-2 dependent complement acitivation |
| KR102339315B1 (ko) | 2012-06-18 | 2021-12-15 | 오메로스 코포레이션 | 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법 |
| SMT202000659T1 (it) | 2013-10-17 | 2021-01-05 | Omeros Corp | Metodi per il trattamento delle condizioni associate all'attivazione del complemento dipendente dalla masp-2 |
| CN108472347B (zh) | 2015-11-09 | 2023-09-05 | 奥默罗斯公司 | 用于治疗与masp-2依赖性补体活化相关的病况的方法 |
| WO2017173290A1 (en) * | 2016-03-31 | 2017-10-05 | Omeros Corporation | Methods for inhibiting angiogenesis in a subject in need thereof |
| JPWO2018070521A1 (ja) * | 2016-10-14 | 2019-08-15 | 公立大学法人福島県立医科大学 | 補体の活性化経路を阻害する融合ポリペプチド |
-
2012
- 2012-04-06 KR KR1020177007747A patent/KR101870915B1/ko active Active
- 2012-04-06 MX MX2018005314A patent/MX381987B/es unknown
- 2012-04-06 JP JP2014504058A patent/JP5937197B2/ja active Active
- 2012-04-06 DK DK12767899.3T patent/DK2694108T3/en active
- 2012-04-06 KR KR1020217004368A patent/KR20210021101A/ko not_active Ceased
- 2012-04-06 KR KR1020227010108A patent/KR20220044616A/ko not_active Ceased
- 2012-04-06 RU RU2018125514A patent/RU2743409C2/ru active
- 2012-04-06 KR KR1020197037437A patent/KR102217658B1/ko active Active
- 2012-04-06 CN CN201910000825.6A patent/CN110075294A/zh active Pending
- 2012-04-06 CA CA3076975A patent/CA3076975C/en active Active
- 2012-04-06 ES ES12767899T patent/ES2683307T3/es active Active
- 2012-04-06 ES ES17191208T patent/ES2894342T3/es active Active
- 2012-04-06 CA CA2977009A patent/CA2977009C/en active Active
- 2012-04-06 MX MX2013011721A patent/MX339002B/es active IP Right Grant
- 2012-04-06 EP EP21188935.7A patent/EP3964233A1/en active Pending
- 2012-04-06 AU AU2012239889A patent/AU2012239889B2/en active Active
- 2012-04-06 MX MX2016006039A patent/MX355648B/es unknown
- 2012-04-06 KR KR1020187017317A patent/KR20180072851A/ko not_active Ceased
- 2012-04-06 PL PL17191208T patent/PL3287142T3/pl unknown
- 2012-04-06 WO PCT/US2012/032650 patent/WO2012139081A2/en not_active Ceased
- 2012-04-06 EP EP12767899.3A patent/EP2694108B1/en active Active
- 2012-04-06 RU RU2013149792A patent/RU2662563C2/ru active
- 2012-04-06 NZ NZ731596A patent/NZ731596A/en unknown
- 2012-04-06 CN CN201280028263.2A patent/CN103781492A/zh active Pending
- 2012-04-06 EP EP17191208.2A patent/EP3287142B1/en active Active
- 2012-04-06 NZ NZ617298A patent/NZ617298A/en unknown
- 2012-04-06 BR BR112013025917A patent/BR112013025917A2/pt not_active Application Discontinuation
- 2012-04-06 CA CA3237802A patent/CA3237802A1/en active Pending
- 2012-04-06 NZ NZ717517A patent/NZ717517A/en unknown
- 2012-04-06 NZ NZ709997A patent/NZ709997A/en unknown
- 2012-04-06 KR KR1020137029501A patent/KR101720562B1/ko active Active
- 2012-04-06 CN CN201710646474.7A patent/CN107638565B/zh active Active
- 2012-04-06 NZ NZ746139A patent/NZ746139A/en unknown
- 2012-04-06 DK DK17191208.2T patent/DK3287142T3/da active
- 2012-04-06 CA CA2832187A patent/CA2832187C/en active Active
- 2012-04-06 US US13/441,827 patent/US8951522B2/en active Active
-
2013
- 2013-10-06 IL IL228758A patent/IL228758B/en active IP Right Grant
- 2013-10-07 CL CL2013002874A patent/CL2013002874A1/es unknown
-
2014
- 2014-12-23 US US14/581,191 patent/US20150239985A1/en not_active Abandoned
-
2016
- 2016-05-11 JP JP2016095034A patent/JP6239030B2/ja active Active
- 2016-12-07 US US15/371,726 patent/US10202465B2/en active Active
-
2017
- 2017-10-31 JP JP2017209894A patent/JP6584476B2/ja active Active
-
2018
- 2018-12-17 US US16/222,188 patent/US20190292272A1/en not_active Abandoned
-
2019
- 2019-01-09 IL IL264172A patent/IL264172B/en unknown
- 2019-09-03 JP JP2019160040A patent/JP6893539B2/ja active Active
-
2020
- 2020-04-23 IL IL274206A patent/IL274206A/en unknown
-
2021
- 2021-09-09 US US17/470,386 patent/US20220089781A1/en not_active Abandoned
-
2025
- 2025-05-21 US US19/214,532 patent/US20260062498A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014512363A5 (https=) | ||
| ES2563646T3 (es) | Composiciones y métodos relacionados con variantes de la proteína A (SpA) | |
| BRPI1010880A2 (pt) | polipeptídeos de hormônio de crescimento e métodos de fazer e usar os mesmos. | |
| JP2017528419A5 (https=) | ||
| JP2015212284A5 (https=) | ||
| PH12019500694A1 (en) | Factor viii compositions and methods of making and using the same | |
| BRPI0806578A8 (pt) | Promotores de lactococcus e usos dos mesmos | |
| EP2829550A3 (en) | Fusion proteins forming trimers | |
| EA201590543A1 (ru) | Основанные на фибронектине каркасные доменные белки, которые связываются с миостатином | |
| EA201790976A1 (ru) | Терапевтические вакцины против hpv16 | |
| WO2009108261A3 (en) | Compositions and methods for the treatment of viral infections | |
| PL397167A1 (pl) | Przeciwnowotworowe bialko fuzyjne | |
| IN2014CN00414A (https=) | ||
| EA201200515A1 (ru) | Полипептиды и их применение | |
| WO2015020913A3 (en) | Influenza hemagglutinin proteins and methods of thereof | |
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| JP2019500414A5 (https=) | ||
| RU2017119773A (ru) | Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение | |
| EA201491277A1 (ru) | Противораковый слитый белок | |
| ATE500265T1 (de) | Synthetische mecp2-sequenz für die proteinersatztherapie | |
| RU2015103816A (ru) | ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E | |
| NZ769391A (en) | Serpin fusion polypeptides and methods of use thereof | |
| WO2010007144A3 (en) | Mutated netrin-4 proteins, fragments thereof and their uses as drugs | |
| JP2019512693A5 (https=) | ||
| WO2018074498A8 (ja) | リムルス属由来の組換え蛋白質及びこれをコードするｄｎａ |